Compare Rocket Lab USA Inc (RKLB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Lab USA Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Rocket Lab USA Inc trades at $68.25 (market cap $43.74B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: Rocket Lab USA Inc is far larger — about 4.3× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Rocket Lab USA Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Lab USA Inc for 29 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| RKLB | XBI | |
|---|---|---|
Market Cap | $43.74B | $10.11B |
Volume | 22,892,581 | 12,903,266 |
Sector | Industrials | Broad Market / Factor |
52-Week High | $150.23 | $169.55 |
52-Week Low | $39.48 | $104.99 |
Typical Hold Time | 29 Days | 38 Days |
Enterprise Value | $41.57B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Lab (RKLB) trades at $68.35, down 4.96% in the last session, reflecting a bearish technical trend. The company's fundamentals show strong revenue growth, with 2026 revenue projected at $769 million, but it remains unprofitable with a net loss of -$165 million. Recent positive news includes securing its largest-ever commercial Electron launch deal with Synspective, boosting its backlog to over 100 missions. Analyst sentiment is predominantly bullish, with a consensus price target of $107.00.
The outlook for RKLB hinges on execution of its growing launch backlog and path to profitability. Investment opportunity lies in its leading position in small satellite launch services and expanding spacecraft business. Key risks include intense competition from SpaceX, high cash burn, and reliance on future Neutron rocket success. The stock offers high growth potential but carries significant execution and valuation risks.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Lab USA Inc
Rocket Lab USA, Inc. is an aerospace manufacturer and small-satellite launch service provider. The company specializes in developing rockets for orbital launch, including its flagship *Electron* vehicle, and is developing the next-generation, reusable *Neutron* rocket. Beyond launch services, Rocket Lab also offers satellite design, manufacturing, and spacecraft component solutions, positioning itself as an end-to-end provider for the space industry.
Read more on RKLB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
